An unprecedented compilation of state-of-the-art advances in clinical research on diabetes and obesity by premier clinical scientists around the world. This volume critically reviews the limitations and strengths of today's major techniques in clinical diabetes research, and then reviews how those methods have been used to carry out cutting-edge studies of carbohydrate, lipid, and protein metabolism in the disease.

An unprecedented compilation of state-of-the-art advances in clinical research by premier clinical scientists around the world. This volume discusses the methods of clinical research and the interpretation of their results in studies of normal individuals, obese subjects, and patients with diabetes mellitus. Along the way, the authoritative contributors writing here illuminate how changes in the hormone action and substrate metabolism of healthy humans may lead to obesity and noninsulin-dependent diabetes mellitus.

Frontiers in Clinical Drug Research - Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases - diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research - Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.The first volume of this series features 6 chapters that cover a variety of topics including: -Angiotensin blockers-Agents targeting advanced glycation end products-Drugs and the peroxisome proliferator activated receptors-Topical Drugs for diabetic complications-Research on Liraglutide-Research on MicroRNAs as agents for diabetes treatment

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The second volume of this series features 7 reviews presenting updates on hormones and several classes of drugs: -Osteocalcin action in glucose metabolism -Sodium-glucose co-transporter 2 (SGLT2) inhibitors -Glucagon-like peptide-1 (GLP-1) mimetics -Dipeptidyl peptidase 4 (DPP-4) inhibitors -New drugs in clinical trial and commercial phases

"Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The third volume of this series features 5 chapters that cover a variety of topics including: -Exendin-4 and its derivatives -The growth hormone/insulin-like growth factor system -Insulin and cardiovascular function -Diabetes mellitus related infertility -Adipocytokines as markers of insulin resistance "

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The fourth volume of this series features 7 chapters: -Pharmacologic Obesity Treatment -Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic Complications -Sodium–Glucose Co-Transporters Inhibitors for Type 2 Diabetes Mellitus -The Effects of Traditional Chinese Medicine on Inflammatory Cytokines in Diabetic Nephropathy -Through the Perspective of Histology – The Alzheimer’s Disease Promotion by Obesity and Glucose Metabolism: Type 3 Diabetes -Pharmacological Mechanism of PPARγ Ratio in Diabetes and Obesity -Hydrogen Sulfide and Carbohydrate Metabolism

The world is beset by a pandemic of obesity and type 2 diabetes and the need for new drugs is startlingly clear; recent years have seen a huge increase in research activity to fill this gap. The development of new drugs for diabetes and obesity must be founded upon a sound appreciation of the pathophysiology of these common disorders. The dual defects of insulin resistance and impaired insulin secretion are fundamental to the pathogenesis and progression of obesity-associated type 2 diabetes. There is a need to explain how new drugs can counter insulin resistance and insulin deficiency to a broad range of professionals, from clinical scientists active in early (and later) phase drug development to specialist physicians and increasingly primary care doctors who must tailor drug regimens to the individual patient. Clinical research methods for measuring insulin action and insulin secretion have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. The purpose of the book is to aid the selection of the most appropriate techniques for assessing insulin action, insulin secretion and body composition in humans (with particular reference to new drugs) in phase 1 and 2 studies and aid the understanding of drug effects and non-drug treatment strategies on key biochemical-hormonal defects of obesity and type 2 diabetes. The book will assume a working knowledge of human physiology relating to glucose metabolism and will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.